Main menu

Joint fragmentomic and methylation signatures of cfDNA for cancer detection


Abstract

Non-invasive detection of cancer by analyzing cell-free DNA (cfDNA) is a rapidly growing field for liquid biopsies. Many methods focus on only one omic type (e.g. SNVs, SVs, methylation, fragmentomics) for discovery and validation of cancer-associated biomarkers. The utilization of more than one omic type is an ongoing challenge due to the lack of sufficient material in cfDNA for multiple assays.

Addressing these limitations, our study presents an innovative nanopore sequencing approach that analyzes cfDNA molecules at single molecule resolution for both methylation and fragmentomic data, requiring only single nanograms or less of cfDNA without PCR amplification. Leveraging novel data analytics and machine learning frameworks, we achieved single molecule resolution of methylation and fragment sizes.

Our analysis of nearly 1,000 individuals, including early-stage breast and colon cancer patients, revealed that integrating multi-omic cfDNA profiles enhances cancer detection. Our statistical framework evaluates both methylation and fragmentomic indicators, benefiting from nanopore sequencing's ability to simultaneously assess methylation and fragment size from the same molecule. We identified a correlation between cancer and the prevalence of mononucleosomes and smaller cfDNA fragments, improving early detection. We observed recurrent CpG sites across samples specific to nucleosome type, which were specific to cancer-associated pathways.

Overall, our study demonstrates the power of nanopore-based cfDNA sequencing for developing joint multi-omic profiles for cancer detection. This may have potentially significant future clinical utility for high accuracy non-invasive early detection of cancer from blood.

Biography

Dr. Billy Lau is an Instructor in the Division of Oncology at Stanford University School of Medicine. His research focus is on leveraging genome technology for cancer detection, and for studying human genomic variation. Dr. Lau received his doctorate from Harvard University in Engineering Sciences, and completed his post-doctoral training with Dr. Hanlee Ji at Stanford University. He has also received the NHGRI’s Genomic Innovator Award, where he focuses on building tools to maximize information from single molecules and cells.

Authors: Billy Lau

入门指南

购买 MinION 启动包 Nanopore 商城 测序服务提供商 全球代理商

纳米孔技术

订阅 Nanopore 更新 资源库及发表刊物 什么是 Nanopore 社区

关于 Oxford Nanopore

新闻 公司历程 可持续发展 领导团队 媒体资源和联系方式 投资者 合作者 在 Oxford Nanopore 工作 职位空缺 商业信息 BSI 27001 accreditationBSI 90001 accreditationBSI mark of trust
Chinese flag